Glenmark Pharmaceuticals Ltd on Friday (February 14) reported a net profit of ₹347.9 crore for Q3FY25, recovering from a net loss of ₹351.3 crore.

Revenue from operations surged 35.1% to ₹3,387.6 crore against ₹2,506.7 crore in the corresponding period of the preceding fiscal.

At the operating level, EBITDA zoomed to ₹600.3 crore in the third quarter over a loss of ₹208.7 crore in the year-ago quarter. The EBITDA margin stood at 17.7% in the reporting quarter. EBITDA is earnings before interest, tax, depreciation, and amortisation.

Also Read: Dish TV India Q3 Results | Net loss widens to ₹47 crore as revenue declines 21%

Glenmark Pharmaceuticals reported strong growth in its India business, with sales from the formulation segment surging 300.2% year-on-year to ₹10,637 million in Q3 FY25.

The Europe business registered a 14.8% YoY increase, reaching ₹7,297 million, while the Rest of the World (RoW) segment grew 3% year-on-year to ₹7,491 million, though currency fluctuations in key markets impacted reported growth.

North America saw marginal growth of 1.4% year-on-year, with revenue from finished dosage formulations rising to ₹7,813 million. Despite the overall positive performance, growth in the RoW region was partially offset by adverse currency movements.

Also Read: Easy Trip Q3 Results | Net profit, margin decline despite 172% rise in hotel bookings

Glenn Saldanha, Chairman and Managing Director of Glenmark Pharmaceuticals, said, “We delivered strong and sustained growth this quarter, driven by robust performance across the regions.

Our European business continued to perform well, while our branded markets demonstrated resilient growth. Strengthening our value-chain strategy, we secured MHRA authorization for WINLEVI in the UK, marking a pivotal step in expanding our dermatology portfolio.”

The results came after the close of the market hours. Shares of Glenmark Pharmaceuticals Ltd ended at ₹1,321.35, down by ₹88.55, or 6.28%, on the BSE.